Immunome prices upsized $150M public offering of common stock at $7.75/share

Immunome Inc.

19,354,839 shares priced at $7.75 per share; gross proceeds $150M.
Underwriters granted 30-day option to buy up to 2,903,225 additional shares.
Offering expected to close Jan 31, 2025, subject to customary closing conditions.
Joint book-running managers: J.P. Morgan, TD Cowen, Leerink Partners, Guggenheim Securities.
Offering upsized from initially announced $125M; all shares sold by Immunome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.